The Long-Term Adverse Event Profile of Oral Eliglustat for the Treatment of Gaucher Disease Type 1: Pooled Analysis of Data from 393 Patients in 4 Completed Trials
Conclusions:This pooled analysis of AE data from one Phase 2 and three Phase 3 completed eliglustat trials demonstrates long-term safety and tolerability of eliglustat in the treatment of adults with GD1.DisclosuresPeterschmitt: Sanofi Genzyme: Employment. Freisens: Sanofi Genzyme: Employment. Hou: Sanofi Genzyme: Employment. Underhill: Sanofi Genzyme: Employment. Foster: Sanofi Genzyme: Employment. Gaemers: Sanofi Genzyme: Employment.
Source: Blood - Category: Hematology Authors: Peterschmitt, M. J., Freisens, S., Hou, A. W., Underhill, L., Foster, M. C., Gaemers, S. J. M. Tags: 201. Granulocytes, Monocytes, and Macrophages: Poster III Source Type: research
More News: Accidents | Acid Reflux | Anemia | Appendicitis | Arrhythmia | Brain | Cancer & Oncology | Carcinoma | Clinical Trials | Dyspepsia | Electrocardiogram | Employment | Gastroenterology | Gastroesophageal Reflux Disease | Gaucher's Disease | GERD | Headache | Hematology | Hepatocellular Carcinoma | Liver Cancer | Migraine | Neurology | Oral Cancer | Orthopaedics | Pain | Peripheral Neuropathy | Pregnancy | Study | Thrombocytopenia | Ventricular Tachycardia | Vertigo